Uniunea Europeană - română - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenți antineoplazici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

celgene distribution b.v. - olanda - fedratinibum - caps. - 100mg - inhibitori de protein-kinaza